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Abstract: Several candidate gene studies have provided
evidence for a role of host genetics in susceptibility to
tuberculosis (TB). However, the results of these studies
have been very inconsistent, even within a study popula-
tion. Here, we review the design of these studies from a
genetic epidemiological perspective, illustrating important
differences in phenotype definition in both cases and
controls, consideration of latent M. tuberculosis infection
versus active TB disease, population genetic factors such as
population substructure and linkage disequilibrium, poly-
morphism selection, and potential global differences in M.
tuberculosis strain. These considerable differences between
studies should be accounted for when examining the
current literature. Recommendations are made for future
studies to further clarify the host genetics of TB.
Introduction
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is a
growing public health problem in the era of the HIV/AIDS
pandemic. Among the one-third of the world infected by Mtb [1],
almost 8 million new cases of TB occur annually, with 2 million
deaths attributed to the disease each year. Only 10% of those
individuals infected by Mtb go on to develop clinical disease, and
disease presentation itself is heterogeneous, suggesting that
host factors play a large role in disease susceptibility and natural
history. An increased understanding of the host response to
Mtb will facilitate the development of new vaccines and
therapeutics [2].
Several studies have suggested a role for host genetics in TB
susceptibility. Support for genetic susceptibility to TB in humans
was first provided by twin studies [3,4], animal models [5–8], then
later segregation analyses [9,10]. Countless candidate gene studies
have been conducted, as well as seven genome-wide linkage scans
[11–17]. However, there is a great deal of inconsistency across
these studies. Among studies of any candidate gene, there are
always several reports that provide both positive and negative
evidence for an association with TB. Within genome scans, there
has been replication of some results across two of the studies
[14,15], but there is very little replication across the remaining
papers.
There are a number of key components of the design of these
studies that may explain the inconsistency in the literature. The
objective of this review is to discuss these issues, illustrated with
examples from the TB genetics literature, and propose some
approaches for taking a more thorough approach to the study of
TB genetics.
Impact of Study Design
Phenotype Definition
The first step in any epidemiological study is to define the criteria
used to diagnose disease. Then, one must define what is meant by
non-diseased individuals (‘‘controls’’). In TB, this is complicated,
because the pathogenesis of TB can be thought of as a two-stage
process [18]. The first stage consists of latent Mtb infection (LTBI),
in which Mtb establishes a productive infection but does not
produce symptoms. LTBI is diagnosed by a positive tuberculin skin
test (TST) and/orpositiveinterferon-c response assay(IGRA)inthe
absence of clinical signs and symptoms of full-blown disease [19,20].
Definitive diagnosis of pulmonary TB requires the recovery of Mtb
from sputum and cultivation in culture or detection of acid-fast
bacilli (AFB) on smear [19,21]. Studies have shown that AFB smear
is less sensitive than culture, and that AFB smear grade could reflect
differences in disease severity [21]. Smear-negative, culture-positive
TBisalso aproblemindeveloping countries[21].Thus,themethod
used to diagnose TB could affect the comparability of studies, and
these differences could reflect variation in disease severity or even
potential misclassification of disease status, generating a significant
impact on the type I and type II error of studies. Here, we will first
review the various diagnostic criteria used for TB disease, then the
clinical characterization of study controls, and how these differences
in study design may affect the interpretation of results across studies.
As stated by Mo ¨ller and colleagues [22], studies of TB are
‘‘exquisitely sensitive to phenotype definition’’. Different criteria
have been used to diagnose TB in different study sites. Here, we
focus on studies of the NRAMP1 (SLC11A1) gene, which has been
studied most extensively (Table 1). To summarize, some studies
have used the gold standard definition for TB diagnosis based on
growth of Mtb in culture [19], though other studies only diagnosed
TB patients based on positive AFB smear. Some studies had
heterogeneous diagnostic criteria, classifying together cases
diagnosed by smear or culture or symptoms. Other studies have
combined pulmonary and extrapulmonary TB cases in the analysis
[23–27]. Notice that of the 12 studies demonstrating an association
between NRAMP1 and TB, only four used culture positivity as
their diagnosis method. Could these differences in diagnostic
criteria disguise differences in disease severity across populations?
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many of these studies whether or not the ‘‘controls’’ were latently
infected with Mtb, as evidenced by either a TST or IGRA. Recent
studies have suggested some genes may actually be related to LTBI
and not progression to TB [15,28,29], while other studies have
suggested some genes may differentiate between LTBI and active
TB disease [30,31]. This is important in truly understanding the
role of these genes in disease pathogenesis and progression. If
controls are latently infected, and there is an association seen
between a gene and TB, that suggests the gene influences
progression from LTBI to TB. However, if controls are uninfected,
it is unclear whether an association implies susceptibility for
developing active disease or just acquisition of LTBI.
Finally, the selection of controls is not trivial. In a case-control
study, controls should be similar to cases in every way possible
except for the presence of disease. In studies of TB, this means
controls should be exposed to infectious TB cases, so that they
have the opportunity to acquire infection and then progress to
active TB disease. Some studies conducted in TB-endemic settings
assume all individuals are exposed to TB [25,32]. However,
studies have shown individuals may be persistently exposed to Mtb
but never develop LTBI [15,19]. Characterization of controls in
TB genetics studies has differed widely (examples in Table 1).
Many studies have utilized population controls, similar to the
approach taken in recent large genome-wide association studies
(GWAS) [33], i.e., by using blood bank donors. The disadvantage
of this design is possible misclassification bias [34]—the chance
that some of these ‘‘controls’’ may never become affected for TB,
which is problematic when the disease is common [35]. By
contrast, other studies have utilized unaffected household
members [26,31,36,37] or have conducted thorough clinical
evaluation with TST in those without disease [27,30,38]; in these
situations, exposure in unaffected individuals is known, so these
are true controls in the epidemiological sense. Note that only one
of the NRAMP1 associations was observed in studies where
exposure has been quantified (Table 1).
Epidemiological Study Design
The vast majority of genetic epidemiological studies, not just for TB
but for other complex traits as well, tend to be case-control studies.
Such studies are easier to conduct because they do not require
cooperation of the entire family, and a greater number of cases can be
Table 1. Summary of TB association genetic studies of NRAMP1/SLC11A1, including TB diagnostic criteria, characterization of
controls, and whether there was an association with any SNP in the gene.
Population (Reference) TB Diagnostic Criteria Characterization of Controls Association?
Gambia [80] Smear + Healthy blood donors Yes
Gambia [81] Smear + Healthy blood donors
Malawi [82] Smear + OR culture
+ OR histology
Unrelated with no history
of infectious disease
Yes
Morocco [37] Culture + Healthy family members
Tanzania [83] Culture + Blood donors Yes
Guinea [36] Microscopy (smear +? Culture +?) Unaffected relatives
South Africa [32] Smear + OR culture + Unrelated healthy Yes
Caucasian and African
American [26]
Culture + OR past diagnosis Household members
in close contact
Yes
Caucasian [84] Culture + OR response
to TB treatment
Clinic patients without
infectious disease
Yes
Caucasian, African
American, and Asian [27]
Culture + Tuberculin skin
test positive
Cambodia [85] Smear + Hospital/clinic patients Yes
China [86] Smear + OR culture + OR symptoms
and radiological evidence; males only
Unrelated healthy males Yes
Japan [87] Smear + OR culture + No history of TB disease Yes
Japan [88] Smear + Random clinic patients Yes
Taiwanese [89] Culture + Clinic patients without
pulmonary disease
Japan [90] Smear + Healthy blood donors
without history of pulmonary
or inflammatory disease
Thai [91] Culture + Healthy blood bank donors
China [92] Culture + Hospital patients and
healthy blood donors
Yes
Korea [93] Culture + (unclear) No history of TB disease Yes
Japan [94] Smear + OR culture + Unrelated healthy
Poland [38] Culture + TST negative
Smear + refers to AFB smear positive. ‘‘Culture +’’ could include more stringent definitions such as culture positive, smear positive, and radiological evidence consistent
with TB.
This table is limited to studies published in English so that case and control definitions could be determined. It is also limited to studies of pulmonary TB in all age
groups.
doi:10.1371/journal.ppat.1001189.t001
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of infectious diseases is the characterization of exposure in the
‘‘controls’’, as discussed above. Individuals living in the same household
have a high likelihood of exposure to an infectious TB case, thereby
influencing the probability that they too will develop TB [39–41]. As
described above, epidemiological characterization of exposure is
important in order to construct a valid case-control study.
Another advantage of family-based studies is the ability to
account for population substructure. Hidden population stratifi-
cation may result in bias (false positive results) [42] or false
negative results [43]. Studies of TB genetics have been conducted
in many admixed populations, including African Americans
[26,27,44–46], Mexicans [30], and South African ‘‘Coloureds’’
[11,14,32,47,48]. Some of these studies [11,26,45,46] have
employed family-based designs. Other studies have examined
potential population substructure by analyzing genomic control
markers: one study in South Africa utilized ,25 markers [47,48],
and another study utilized .200 markers [49]. Marchini et al. [43]
point out genomic control markers will not adequately correct for
population substructure if too few markers are used, but it is
difficult to enumerate a sufficient number of markers in
populations of African descent. It is unclear if other studies were
able to account for population substructure. It may be impossible
for existing study cohorts to incorporate family-based designs or
retrospectively evaluate population stratification, but this clearly
may explain some of the heterogeneity among studies.
Population Differences—More Than Just Geography
A typical explanation for differing results by population is
population differentiation [22,50], including genetic heterogeneity
or inestimable polygenic effects. Another important genetic
difference between populations is in linkage disequilibrium (LD).
Early studies of TB genetics were restricted to well-character-
ized markers within genes (studies of SLC11A1/NRAMP1 in
Table 1 are examples). Often these markers were exonic or
restriction fragment length polymorphisms. The underlying
assumption of the power and design of such studies is that the
polymorphism being analyzed is the causal polymorphism.
There are millions of single nucleotide polymorphisms (SNPs)
throughout the genome [51,52]. Because of the LD structure in the
genome, certain SNPs can be used to ‘‘tag’’ haplotypes, such that one
or a few SNPs capture information about LD structure [53]. Many
trait-associated SNPs (.40%) are intergenic or intronic, suggesting an
important role for non-coding SNPs in complex disease [54]. This
serves as a reminder that disease risk alleles may actually be in LD with
genotyped markers, which serve as ‘‘tags’’ for haplotypes on which the
causal allele may reside. This is illustrated by Figure 1, where we
consider an underlying disease allele that is not directly genotyped but
surrounded by flanking markers. The ability to detect association with
the region where the disease allele resides depends entirely on the
strength of LD between the unobserved risk allele and flanking
markers. As patterns of LD differ between study populations, the
specific trait-associated SNPs will consequently differ.
Figure 1. Impact of variation in linkage disequilibrium (LD) in detection of disease risk alleles. For all three scenarios, D is the underlying
disease risk allele. (A) There is strong LD between D and marker #1 (M1), and weak LD between D and M2. In this situation, association will be
detected with M1, depending on study power based on sample size, strength of genetic effect, and minor allele frequencies. (B) There is no LD
between M1 and D but strong LD between M2 and D. Here, association will be detected only with M2 (again, depending on power). (C) There is weak
LD throughout the region. Association will likely not be detected.
doi:10.1371/journal.ppat.1001189.g001
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further illustrated in Figure 2. Here, LD patterns in NRAMP1 were
plotted using HapMap reference populations representative of
those populations where NRAMP1 has been studied: Caucasians
in Utah, United States (CEU), Yoruba in Nigeria (YRI), Maasai in
Kenya (MKK), Han Chinese (CHN), and African Americans in
the US Southwest (ASW). These LD plots were generated using
default parameters in the Genome Variation Server (http://gvs.gs.
washington.edu/GVS/), with no minor allele frequency cutoff.
African populations (YRI and MKK) have very little LD because
they are older populations, and their LD patterns differ. Newer
populations (CEU and CHN) have much greater LD, and recently
admixed populations (ASW) also exhibit LD between SNPs, but
there are differences. Also note that the SNPs themselves (rs
numbers) differ between populations, illustrating how different
polymorphisms exist within the same genes across world
populations. A perfect illustration of this phenomenon is provided
by Velez et al. [26], who analyzed a number of SNPs within
NRAMP1. Though they did not observe statistical association with
the markers that were examined in early studies, they did observe
association with intronic and exonic SNPs. If they had not
conducted such extensive genotyping, they may have missed these
associations.
Only a few other studies have accounted for global variations in
LD by analyzing several SNPs within candidate genes of interest.
Some studies have selected tag SNPs based on relevant HapMap
reference populations [26,28,31,46]. Other studies have sequenced
genes of interest first to identify novel SNPs within the gene(s), then
analyzed association with those SNPs [55–58]. Though other
studies did not utilize LD in their selection of SNPs, they later
estimated LD between markers in their dataset, and used this
analysis to guide haplotype analysis [48,49]. Since LD patterns
differ by population, it should not be surprising that genetic
association results differ, especially given the limited number of
markers analyzed per gene. There are many implications of this
variation. Differences in the strength of LD between the actual
disease locus and genotyped markers will affect the power to detect
association to markers (Figure 1). In populations with weaker LD
such as African populations, denser SNP observed maps are
necessary to detect association effects with untyped disease loci.
Thus, variation in number of polymorphisms analyzed, differences
in LD in the reference population, and existence of still-unknown
risk alleles all complicate replication across studies.
Another controversial issue is the study of common versus rare
genetic variants. The common disease–common variant (CDCV)
hypothesis posits that genetic risk for common diseases will often
be due to common risk alleles [59]. This is in contrast to the
common disease rare variant (CDRV) hypothesis, which states
that a significant proportion of common chronic diseases are
influenced by the summation of effects of multiple low frequency
variants in the same gene, where tagging SNPs will not be useful in
identifying a single haplotype because no single haplotype exists
[60]. Most candidate gene studies assume the CDCV hypothesis.
Recent sequencing studies [61,62] have detected rare SNPs in the
TLR family of genes; these could be important, but massive studies
will be needed in order to detect disease associations at a
statistically significant threshold. In addition, copy number
variants (CNVs) have recently attracted attention in their
association with complex traits, such as HIV acquisition and
progression and autoimmune diseases [63]. These are also
considered rare variants, so we are again faced with all of the
challenges of testing the CDRV hypothesis.
The above discussion focuses on population genetics of humans.
Another related issue is variation in Mtb strains. Researchers have
categorized Mtb into six main bacterial strain lineages that are
associated with particular geographical regions [64], as well as
differences in clinical presentation [65] and rate of progression to
active TB disease [66]. So, not only do different diagnostic criteria,
as discussed above, potentially reflect differences in disease
severity, but specific Mtb strains may also influence disease
severity. A recent study suggests a host genotype x Mtb genotype
interaction, whereby the TLR2 genotype is associated with TB
caused by the Beijing strain [67]. Very few studies have the
capacity to examine this potential host by Mtb interaction, but it
could easily be a potential explanation for differences between
studies.
Complex Genetic Effects
Complex traits such as TB are likely influenced by several
factors, including gene–gene interaction and gene–environment
interaction. Few studies have investigated gene-gene interactions
in the context of human TB. Many gene products (e.g., Toll-like
Figure 2. Linkage disequilibrium (LD) of the NRAMP1 gene for HapMap reference populations. Yoruba (YRI), Maasai (MKK), Han Chinese
(CHN), Utah Caucasians (CEU), and African Americans (ASW) are shown. The strength of LD is illustrated using the color scale shown in the figure key.
doi:10.1371/journal.ppat.1001189.g002
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interaction effects have been demonstrated in mouse models of TB
[69]. A recent study identified interactions between the NOS2A
gene and IFNGR1 and TLR4 [45]. Interestingly, both IFNGR1 and
TLR4 showed no evidence of significant main effects in this
analysis. Another study by the same research group found
interaction between NRAMP1 and TLR2, but TLR2 did not itself
have a significant main effect [26]. This suggests many important
genes may influence TB in combination with other genes, but this
could be overlooked because their individual effects did not meet
criteria for statistical significance. Motsinger-Reif et al. used
multifactor dimensionality reduction to identify a potential gene–
gene interaction between TLR4 and the TNF-a gene (TNF) [70].
In addition, it is well known that HIV influences the pathogenesis
of TB, but most genetic epidemiological studies have been
restricted to HIV seronegative individuals. Our work [31] showed
an interaction between HIV and the TNF receptor 1 gene.
Because many studies have excluded HIV-positive individuals, this
hypothesis remains relatively unexplored. Similar to the TNF-a
pathway, the type I and II interferon pathways have been
associated with both TB and HIV pathogenesis [71], and so
should also be considered for future studies of gene–HIV
interactions. The challenge of examining interaction effects is
the requirement of even larger sample sizes, as discussed by Velez
et al. [45].
Conclusions, Recommendations, and Future
Directions
As reviewed recently by Mo ¨ller et al. [22], the body of work
showing statistical associations between candidate genes and TB
continues to grow. This does not include potential unpublished
studies that failed to find significant associations and are not
readily available due to publication bias [22]. Even in the
published body of literature, however, there is a great deal of
inconsistency between marker-trait associations, so we are far from
reaching a consensus regarding genes involved in TB risk.
This review focused on methodological reasons for inconsisten-
cy across studies. One important factor is the diagnostic criteria for
TB disease, which have differed dramatically across studies.
Resources available for TB diagnosis differ by country, which is
confounded when there has been conflict [72]. Differences in
diagnostic criteria across studies can reflect differences in TB
severity and may lead to misclassification of cases as controls; this
would have a significant impact on the type I and type II error of
studies. It is impossible to standardize the diagnostic definitions
used across all study sites, but researchers should be mindful of
such differences when interpreting their findings. We strongly
recommend that researchers characterize the level of exposure to
Mtb in individuals without disease, which should include TST/
IGRA and careful epidemiological characterization. New studies
could utilize the household contact design, which facilitates the
characterization of all stages of Mtb exposure, infection, and
disease [41]. When the household contact study design is not
feasible, spousal controls are also ideal because of persistent and
prolonged exposure.
Recall that TB follows two stages of pathogenesis, and LTBI
precedes TB disease. Recent studies suggest that LTBI may have
unique genetic influences [15,28,29]. Persons with LTBI constitute
a major impediment to TB control efforts [73]. Since many
ongoing vaccine development efforts will focus either preventing
LTBI or progression to TB, it is important to understand host
factors that influence containment of Mtb infection. However, the
study of the genetics of LTBI is also not trivial. Indication of T cell
memory response via positive TST and/or IGRA does not
necessarily imply the presence of viable Mtb bacilli. In the US as
well as other public health systems, individuals with positive TST
are treated as though there are viable organisms present, adding
further confusion to this phenotype. According to Parrish et al.,
there is a 2%–23% lifetime probability of developing TB after
acquisition of Mtb infection (LTBI) [73]. This illustrates the
heterogeneity in this clinical group, since the risk of progression to
active TB may depend on a variety of known and unknown risk
factors. Furthermore, prophylaxis of LTBI with isoniazid (INH) is
the standard of care in many research settings, so that many
individuals with ‘‘LTBI’’ based on positive TST/IGRA, geneti-
cally predisposed to develop TB, may not. One way to investigate
the role of host genetics in LTBI would be to compare TST (or
IGRA) positive individuals that develop incident TB to those that
do not. Ideally, such a study would not include individuals on INH
prophylaxis, though that is unethical in many settings. For these
reasons, some may argue that it is more relevant to study TB
genetics, and not LTBI, from a public health standpoint.
Thus, it is essential to take a multidisciplinary approach [74] to
develop an all-encompassing picture of the natural history of Mtb
infection and disease. Few studies have examined the genetics of
TB immunology [15,31,75–77]. Gene expression studies using
microarrays may also shed light on host responses to Mtb [78].
Proteomic studies will further elucidate host factors involved in
pathogenesis. These various approaches should be analyzed
together to hopefully identify more meaningful clinical groups.
For example, genomic, proteomic, and immunologic data,
collectively, may better capture the heterogeneity in latently
infected individuals.
Additional complicating factors in comparing geographically
diverse studies are potential population substructure and LD
differences among populations. We recommend that future studies
analyze enough SNPs to capture LD in their study population.
Analyses of a few markers within a gene no longer advance the
field, particularly in light of LD differences between populations.
Even with advances in genotyping, many studies of ‘‘old’’ markers
continue to be published. The choice of a reference population for
tag SNP selection is not trivial [62]; thus, dense SNP mapping may
be necessary, particularly in studies of African populations. If it is
impossible to rigorously examine genes in this way, publishing the
LD patterns in the study data [28,45,48,49] is a good start.
Furthermore, studies in admixed populations should attempt to
examine population substructure to minimize this source of bias.
Populations also differ in the Mtb strain lineage that caused TB;
future studies examining host gene by Mtb gene interaction are
warranted. Finally, as in all genetic epidemiological studies of
complex traits, genes may act in complex ways. Genes may
interact with other genes and/or epidemiological factors; these
potential relationships should not be overlooked. Furthermore, too
many researchers (authors and journal reviewers alike) focus too
much on p-values. All p-values must be reported, even if greater
than 0.05. Markers with p-values greater than 0.05 may still be
important in their interaction with other markers or environmen-
tal factors. Researchers should collect sufficient data to explore
these meaningful biological effects.
There are GWAS of TB forthcoming. Given the issues discussed
in this review, we must interpret the findings of those GWAS
cautiously. Will these studies be underpowered due to the
heterogeneity among TB cases and controls? A recent summary
analysis of published GWAS found the reported SNP–trait
associations attaining significance (p,10
25) had a median odds
ratio of 1.33, with an interquartile range of 1.20–1.61 [54]; thus,
the effect sizes of SNPs identified through GWAS are relatively
PLoS Pathogens | www.plospathogens.org 5 January 2011 | Volume 7 | Issue 1 | e1001189small. Furthermore, the proportion of heritability explained by
these variants ranges between 1% and 50% [79]. TB GWAS may
provide new clues into the host biology of TB pathogenesis, but
the overall clinical relevance of these SNPs will be limited. In
addition, GWAS of other complex traits have often merged data
across ongoing research studies. Because of the dramatic
heterogeneity among studies described in this review, meta-
analyses of TB genetic association studies should be conducted
with care.
In sum, we have barely scratched the surface in understanding
the genetic determinants of TB pathogenesis. Because of the
significant public health impact of TB, additional studies are
necessary, and should be multidisciplinary in nature. Future
studies should carefully consider phenotype definition and genetic
epidemiological principles when designing, analyzing, and inter-
preting findings. Ideally, culture confirmation for pulmonary TB
should be conducted where feasible, thorough epidemiological
data should be collected in individuals without TB to better
understand LTBI and risk of progression to TB, and population
genetic factors should be carefully characterized and considered in
the analysis.
Accession Numbers for Genes Mentioned in This Paper
(GeneIDs from EntrezGene)
TLR2 (7097); SLC11A1, aka NRAMP1 (6556); IFNGR1 (3459);
TLR4 (7099); TNF (7124); TNFSF1A, aka TNF receptor 1 (7132);
NOS2A (4843).
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